Lexicon Pharmaceuticals (LX31) Ownership - Who Owns Lexicon Pharmaceuticals?
5 Followers
Lexicon Pharmaceuticals (LX31) Ownership Overview
- 61.24% Insiders
- 12.82% Mutual Funds
- 0.28% Other Institutional Investors
- 5.94% ETFs
- 19.72% Public Companies and Individual Investors
The ownership structure of Lexicon Pharmaceuticals (DE:LX31) stock is a mix of institutional, retail, and individual investors. Approximately 19.04% of the company’s stock is owned by Institutional Investors, 61.24% is owned by Insiders, and 19.72% is owned by Public Companies and Individual Investors.
The ownership structure of Lexicon Pharmaceuticals (DE:LX31) stock is a mix of institutional, retail, and individual investors. Approximately 19.04% of the company’s stock is owned by Institutional Investors, 61.24% is owned by Insiders, and 19.72% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Feb 26, 2026 | Raymond Debbane | $2,980 | |
| Feb 24, 2026 | Raymond Debbane | $147,000 | |
| Feb 22, 2026 | Raymond Debbane | $218,500 | |
| Feb 17, 2026 | Raymond Debbane | $351,720 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Entrypoint Capital, Llc | €38,660 | |
| Dec 31, 2025 | Graham Capital Management, L.p. | €126,385 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Artal Participations S.a R.l. | 175,156,062 | Insider | 39.36% | 198,451,818 |
| Raymond Debbane | 51,750,221 | Insider | 11.63% | 58,633,000 |
| Invus Global Management, Llc | 42,606,727 | Insider | 9.58% | 48,273,422 |
| Fidelity Mt. Vernon Street Trust | 31,778,399 | Institution | 7.14% | 36,004,926 |
| BlackRock, Inc. | 17,348,741 | Institution | 3.90% | 19,656,124 |
| Vanguard | 12,397,111 | Institution | 2.79% | 14,045,927 |
| Vanguard Index Funds | 9,650,961 | Institution | 2.17% | 10,934,539 |
| Ishares | 8,777,214 | Institution | 1.97% | 9,944,583 |
| Fidelity Select Portfolios | 5,708,045 | Institution | 1.28% | 6,467,215 |
| Fidelity Salem Street Trust | 2,990,331 | Institution | 0.67% | 3,388,045 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust | 31,778,399 | Institution | 7.14% | 36,004,926 |
| Vanguard Index Funds | 9,650,961 | Institution | 2.17% | 10,934,539 |
| Fidelity Select Portfolios | 5,708,045 | Institution | 1.28% | 6,467,215 |
| Fidelity Salem Street Trust | 2,990,331 | Institution | 0.67% | 3,388,045 |
| Fidelity Concord Street Trust | 2,311,764 | Institution | 0.52% | 2,619,229 |
| Vanguard Scottsdale Funds | 1,717,345 | Institution | 0.39% | 1,945,752 |
| Schwab Capital Trust | 754,413 | Institution | 0.17% | 854,750 |
| Tiaa-cref Funds | 699,261 | Institution | 0.16% | 792,263 |
| Vanguard World Fund | 645,289 | Institution | 0.15% | 731,112 |
| Vanguard Valley Forge Funds | 122,411 | Institution | 0.03% | 138,692 |
FAQ
Who Owns Lexicon Pharmaceuticals (DE:LX31)?
According to the latest TipRanks data, approximately 19.04% of the company's stock is held by institutional investors, 61.24% is held by insiders, and 19.72% is held by public companies and individual investors.
What percentage of Lexicon Pharmaceuticals (DE:LX31) stock is held by institutional investors?
According to the latest TipRanks data, approximately 19.04% of Lexicon Pharmaceuticals (DE:LX31) stock is held by institutional investors: 12.82% by mutual funds, 5.94% by ETFs and 0.28% by other institutional investors.
What percentage of Lexicon Pharmaceuticals (DE:LX31) stock is held by retail investors?
According to the latest TipRanks data, approximately 19.72% of Lexicon Pharmaceuticals (DE:LX31) stock is held by public companies and individual investors.
Who owns the most shares of Lexicon Pharmaceuticals (DE:LX31)?
Artal Participations S.a r.l. owns the most shares of Lexicon Pharmaceuticals (DE:LX31).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
